MEDTECH NEWS

China's National Medical Products Administration (NMPA) has issued Notice No. 14 of 2026, releasing new inspection guidelines aligned with the revised Medical Device Production Quality Management Regulations (GMP), which take effect November 1, 2026. The guidelines replace the 2015 version and set out transition arrangements, risk-based post-market inspection requirements, and specify that sterile, implantable, IVD reagent, custom denture, and standalone software devices must comply with both the new GMP and existing appendix requirements.

On June 8, 2026, China's NMPA, jointly with three other national health authorities, issued the revised "Good Clinical Practice for Drug Clinical Trials," effective September 1, 2026, replacing the 2020 version. The update aligns closely with ICH E6(R3), restructuring the GCP into six chapters and adding a new Data Governance chapter to strengthen data reliability and traceability. It sharpens accountability—designating principal investigators as ultimate on-site responsible parties and sponsors as bearing final trial responsibility—while reinforcing participant protections, particularly for vulnerable populations and informed consent.

China's National Medical Products Administration (NMPA) issued Announcement No. 52 (2026) on June 1, 2026, establishing comprehensive procedural requirements for the registration and filing of medical devices — including in vitro diagnostic reagents — following regulatory classification adjustments. The announcement addresses a broad range of scenarios, including first-time registration, renewal, product changes, and transitions between filing and registration categories, while setting clear deadlines and responsibilities for both manufacturers and regulatory authorities. Products that fail to obtain valid registration or complete required filings before the applicable transition deadline will be prohibited from manufacture, distribution, and import. The announcement took effect immediately upon publication.

On April 8, 2026, China's NMPA officially launched its 2026 National Medical Device Quality Sampling Inspection Program, covering 74 device categories spanning implantables, diagnostics, therapeutic equipment, and surgical consumables. Provincial and national testing institutions are mandated to conduct inspections against mandatory standards and approved product technical specifications, with non-compliant manufacturers required to immediately implement risk control measures — and cases involving potential criminal liability referred to judicial authorities. The program reflects China's continued commitment to strengthening medical device quality oversight and advancing patient safety across a broad spectrum of high-risk and high-value device categories.

On February 28, 2026, China's NMPA Center for Medical Device Evaluation (CMDE) released Announcement No. 8, introducing new registration review guidance for the reliability evaluation of CT X-ray tube assemblies. The guidance establishes standardized requirements for manufacturers to define and validate a reliability index — covering service life, confidence levels, and scan capacity — through either verification or determination-based testing approaches, including both normal-condition and accelerated life testing. It also mandates Failure Mode, Effects, and Criticality Analysis (FMECA), performance testing across key parameters such as focal spot size, radiation dose, and image quality, and proper documentation in the registration dossier. Applicable to both standalone tube assembly registrations and those submitted as part of a complete CT system, this guidance signals China's continued drive to align its medical device regulatory standards with international benchmarks, and serves as essential reading for domestic and global manufacturers navigating NMPA market entry for CT-related products.

China's NMPA Center for Medical Device Evaluation has released revised registration guidelines for endotracheal tube products on January 9, 2026. The 2026 edition applies to Class II passive endotracheal tubes and establishes comprehensive requirements across regulatory documentation, technical specifications, non-clinical research, and labeling. Key provisions include mandatory risk management per GB/T 42062 standards, biocompatibility testing, sterilization validation with SAL of 1×10⁻⁶, and special labeling requirements for DEHP-containing PVC products. While endotracheal tubes remain exempt from clinical evaluation requirements, manufacturers must demonstrate product equivalence unless involving new materials or mechanisms.

China's National Medical Products Administration (NMPA) has released updated regulations for medical device export sales certificates, effective May 1, 2026, replacing the 2015 version. The new rules establish two certificate types: Type I for devices already registered in China and Type II for unregistered devices whose manufacturers meet GMP standards. Applications will be processed within 20 working days through provincial authorities, with certificate validity capped at three years for Class I devices. The regulations introduce stricter accountability measures, including a five-year ban for fraudulent applications, while emphasizing that companies remain responsible for ensuring compliance with importing countries' requirements. The NMPA characterized the update as a service measure to facilitate medical device exports while maintaining quality and regulatory standards.

China's National Medical Products Administration (NMPA) has launched a comprehensive public consultation on 26 medical device registration guidelines, announced on December 11, 2025. The consultation includes two guidelines requiring higher-level review: a newly drafted guideline on glaucoma drainage devices for minimally invasive glaucoma surgery (MIGS) implantation and a 2025 revised version of the central venous catheter registration guideline. Additionally, 24 Class II medical device registration guidelines are open for comment, covering products such as anesthesia reservoir bags, implantable contraceptive devices, coronary guidewires, acupuncture needles, glass infusion containers, disposable syringes, hemoglobin testing reagents, nasal airways, umbilical cord clamps, bone scissors, collagen dressings, suction heads, disposable protective clothing, and various catheter-based devices. Stakeholders are invited to submit feedback by January 9-10, 2026, depending on the specific guideline. This initiative reflects NMPA's systematic effort to update and strengthen regulatory frameworks for medical device registration and evaluation across multiple product categories.

China's National Medical Products Administration (NMPA) has released new comprehensive registration review guidelines for disposable anesthesia needles, effective immediately as of October 11, 2025. The guidelines cover four main types of anesthesia needles classified as Class III medical devices, establishing stringent technical standards for physical performance, chemical safety, and sterility requirements. Key provisions include specific endotoxin limits, biocompatibility testing protocols, and comprehensive risk management throughout the product lifecycle. Many devices may qualify for exemption from clinical evaluation, potentially streamlining the approval process. The new regulations aim to standardize quality requirements across the industry, enhance patient safety during anesthesia procedures, and align Chinese standards with international best practices. This regulatory update reflects China's commitment to strengthening medical device oversight while providing clear pathways for manufacturers to bring safe and effective anesthesia products to market.

China's National Medical Products Administration (NMPA) has issued new comprehensive guidelines for medical device registration self-inspection, effective September 16, 2025. The regulations require companies to integrate self-inspection capabilities into their quality management systems, maintain qualified full-time personnel, and ensure proper equipment and facilities for testing Class II and III medical devices. Key requirements include stringent quality control procedures, comprehensive record-keeping, and compliance with Good Manufacturing Practices. Regulatory authorities will conduct oversight inspections focusing on personnel qualifications, equipment adequacy, and quality control measures. The guidelines aim to strengthen China's medical device regulatory framework while aligning with international best practices, though they do not apply to companies that outsource all testing to qualified institutions. This regulatory enhancement is expected to significantly impact how medical device manufacturers approach registration testing and quality management in the Chinese market.

China's National Medical Products Administration Center for Medical Device Evaluation (NMPA CMDE) has released comprehensive technical review guidelines for chikungunya virus nucleic acid detection reagents, effective August 28, 2025. These guidelines establish stringent requirements for Class III in vitro diagnostic products, covering analytical performance standards including precision testing, cross-reactivity studies, and detection limit determination using statistical models. Clinical evaluation must be conducted at minimum three qualified institutions in epidemiologically relevant regions, with sample sizes meeting statistical requirements for at least 90% positive/negative concordance rates. The guidelines reflect China's enhanced regulatory oversight of diagnostic products for emerging infectious diseases, requiring manufacturers to align development and registration strategies with these technical standards to ensure market compliance. This initiative strengthens guidance for medical device registration applications while addressing the critical need for accurate diagnostic tools for chikungunya fever, a mosquito-borne viral disease causing fever, joint pain, and rash.

China’s NMPA has released the 2025 catalog of in vitro diagnostic (IVD) reagents exempt from clinical trials. The updated list streamlines the registration process for IVD manufacturers, clarifies eligible products, and excludes self-testing and newborn screening reagents. The catalog takes effect immediately from its publication.

China’s National Medical Products Administration issued new guidelines for classifying next-generation sequencing (NGS) in vitro diagnostic (IVD) reagents. Effective immediately, the guidance clarifies management and registration requirements, urges proper classification, and mandates updated filings. If reclassification is required under the new Guidance, registration with the appropriate authorities is needed. Starting January 1, 2027, unregistered products may not be manufactured, imported, or sold.

China’s National Medical Products Administration (NMPA) released the 2025 catalogue of medical devices exempt from clinical evaluation, expanding the list to 1,047 types of products, with 27 new additions such as 3D-printed surgical models. The updated list took effect immediately to streamline device registration and management.

China’s National Medical Products Administration released revised guidelines for mobile medical device registration (2025). The new document clarifies technical requirements, risk management, and cybersecurity standards for handheld, wearable, and software devices, aiming to ensure safety and regulatory consistency as mobile healthcare technologies advance. The rules take effect immediately.

China's NMPA released the 2025 Medical Device Standards Plan, detailing 6 mandatory and 79 recommended standards covering AI, nanotechnology, biomaterials, and robotics. Some standards align with international benchmarks to enhance global competitiveness. The plan promotes high-quality development through collaboration among regulatory bodies, ensuring safety, innovation, and compliance.

China's National Medical Products Administration updated policies to facilitate domestic production of imported Class II and III medical devices. The measures simplify registration through shared materials, prioritize innovative products, and ensure quality control through system inspections. These reforms aim to attract foreign investment, streamline processes, and enhance China's medical device industry.

China's National Healthcare Security Administration (NHSA) has issued new trial guidelines for neurological medical service pricing, reorganizing services into 82 basic items, 24 additional charges, and 8 expanded items. This reform enables provincial authorities to establish price benchmarks and allows local adjustments, advancing China's healthcare pricing standardization efforts.

China's NMPA has announced new guidelines (No. 22 of 2025) for medical device clinical trial inspections, effective May 1, 2025. The rules establish clear criteria for evaluating both pending applications and approved devices, focusing on authenticity and compliance. This update replaces 2016 and 2018 regulations, strengthening clinical trial oversight.

The National Medical Products Administration (NMPA) of China has announced 10 new medical device industry standards. These standards cover various medical devices including hemodialysis systems, surgical implants, high-frequency ventilators, and in vitro diagnostic reagents. The standards will be implemented between March 2026 and March 2028, aiming to enhance medical device safety and quality control.

In 2024, China's medical device standardization system reached a significant milestone with over 2,000 active standards. The advancement reflects a transition from broad framework to detailed implementation, strengthening industry regulation and safety assurance under the "Four Strictest" requirements in healthcare management.

The Shanghai Municipal People's Congress has approved new Pharmaceutical and Medical Device Regulations, effective March 1, 2025. The regulations strengthen product supervision while promoting innovation, featuring digital oversight, streamlined approval processes, and enhanced quality management. Key focuses include R&D support, regional cooperation, and safety standards modernization.

China's State Council has announced two minor amendments to the Medical Device Supervision and Administration Regulations, set to take effect on January 20, 2025. The changes involve administrative authority adjustments and the removal of outdated terminology.

China's State Council has released comprehensive guidelines aimed at reforming drug and medical device regulation through 2035. The plan focuses on accelerating industry innovation, streamlining approval processes, and enhancing regulatory oversight to transform China into a global pharmaceutical powerhouse.

The General Office of the National Medical Products Administration (NMPA) of China has released a draft announcement titled "Announcement on Further Clarifying Matters Related to the Production of Imported Medical Device Products by Enterprises Within China (Draft for Comments)". The NMPA is now openly soliciting public opinions on this draft to deepen medical device regulatory reforms and promote high-level industrial openness, aiming to better meet the public's needs for medical devices.

The National Medical Products Administration conducted a national inspection on 7 categories of medical devices, finding 11 batches/units that did not meet quality standards, including issues with ultrasound therapy equipment, high-frequency electrosurgical units, nebulizers, limb compression therapy equipment, dental cements, and dental products. The administration has ordered provincial authorities to take enforcement actions, require the manufacturers to assess risks, recall the non-compliant products, investigate the causes, and implement corrective measures.

China Beijing has announced a new initiative to streamline the import process for urgently needed drugs and medical devices on September 20, 2024. The Beijing Municipal Medical Products Administration, along with three other departments, has issued a trial implementation plan to create a "green channel" for the temporary import of clinically urgent medications and medical equipment.

China's NMPA has released updated guidelines for Class III ultrasound imaging devices. Announced on October 14, 2024, the revised document aims to standardize management of these medical devices. It covers registration requirements, safety standards, software validation, and clinical applications. The guidelines reflect current regulations and technological advancements, serving as a resource for manufacturers and reviewers.

China's National Medical Products Administration announced 34 new medical device industry standards on October 8, 2024. These standards cover various areas including dental materials, blood purification equipment, ophthalmology instruments, surgical implants, AI in medical devices, robotic surgical systems, genetic testing kits, and tissue engineering materials. The standards aim to regulate performance, safety, and quality requirements, reflecting technological advancements in China's medical device industry. Implementation dates range from 2025 to 2027.

In a recent announcement, China's National Medical Products Administration (NMPA) revealed the results of its latest medical device quality inspection, examining 17 categories of products. Out of these, 24 batches failed to meet the required standards. Key issues were found in high-frequency electrosurgical units from Gebrüder Martin GmbH & Co.KG and a Chinese company, intense pulsed light therapy devices from ActiveOptical Systems Ltd., pulse oximeters from various Chinese manufacturers, and other products such as scar repair gel, arthroscopes by ConMed Corporation, soft contact lenses, hydrocolloid dressings from Paul Hartmann AG, and medical protective masks and clothing. The NMPA has directed local authorities to enforce administrative actions, requiring companies to conduct risk assessments, recall products if necessary, and implement corrective measures. This inspection underscores China's dedication to maintaining high standards of quality and safety for medical devices in the market, impacting both domestic and international companies.

China's National Medical Products Administration, in collaboration with the National Health Commission, has implemented regulations for the temporary import and use of essential medical devices in response to urgent clinical needs. The guidelines prioritize public health, outlining responsibilities, application processes, and usage requirements for medical institutions. The directive targets second and third-class medical devices unavailable domestically for critical life-saving treatments. Furthermore, the initiative ensures adherence to quality standards and patient safety in leading medical institutions. Ongoing support and training initiatives are planned to address specific medical needs effectively.

The National Medical Products Administration (NMPA) announced new regulations requiring all radiofrequency therapy devices and radiofrequency skin therapy devices to obtain valid medical device registration certificates by April 1, 2026, to ensure product safety and quality. Certificates expiring before this date can be extended until March 31, 2026.

On July 8, 2024, the National Medical Products Administration (NMPA) announced amendments to the YY 0167-2020 and YY 1116-2020 standards for non-absorbable and absorbable surgical sutures, respectively. Effective 12 months from approval on July 1, 2024, these updates aim to enhance the quality and safety of surgical sutures, aligning with both current medical needs and international standards.

The National Medical Products Administration (NMPA) has released the results of its national supervision and sampling inspection of medical devices, revealing that seven batches of products, including semiconductor laser therapy machines, medical pulse oximeters, and orthodontic wires, failed to meet required standards. The non-compliant items were found to have issues with input power, data integrity, and physical dimensions among others. The NMPA has mandated provincial regulatory authorities to enforce corrective measures, conduct risk assessments, and ensure public disclosure of product recalls.

NMPA has approved new measures to enhance the supervision of medical device clinical trial institutions. These measures, effective from October 1, 2024, aim to clarify regulatory responsibilities, standardize inspection procedures, and ensure the protection of trial participants' rights and safety. The initiative emphasizes the importance of trial quality and outcome authenticity. In support, the NMPA will soon release detailed inspection guidelines and conduct training sessions to improve regulatory capabilities.

On May 31, 2024, the National Medical Products Administration (NMPA) released information about five recent cases of illegal online sales of medical devices. The NMPA has taken stern actions to regulate the online sale of medical devices to protect public health and ensure device safety.

On May 27, 2024, the Center for Medical Device Evaluation (CMDE) of the National Medical Products Administration (NMPA) released 48 new guidelines for the registration review of various medical devices, including electric photography beds. The guidelines cover a wide range of medical device categories, such as diagnostic equipment, therapeutic devices, auxiliary equipment, rehabilitation tools, and in vitro diagnostic reagents. These guidelines aim to standardize the registration process, enhance industry standards, and ensure the safety and effectiveness of medical devices. Detailed guidelines for specific devices, including medical gas alarm systems, air-oxygen blenders, radiotherapy laser positioning devices, and various testing reagents, are provided to support manufacturers in meeting regulatory standards. The full texts of these guidelines are available on the NMPA's official CMDE website.

This article outlines the clinical trial design for assessing the safety and effectiveness of a single-port laparoscopic surgical system in gynecological surgeries. The trial adopts a prospective, single-group design, targeting common high-risk gynecological procedures. Key evaluation metrics include the non-conversion rate and complications graded Clavien-Dindo 3 or higher within 30 days post-operation, alongside secondary endpoints like surgery duration, intraoperative blood loss, patient pain scores, and overall complication rates. With a sample size of 60 cases, determined from expected performance data and dropout rates, the trial covers representative procedures such as radical hysterectomy and comprehensive staging surgery for endometrial cancer. Statistical analysis follows established guidelines to ensure rigorous assessment of the system's efficacy and safety.

The National Medical Products Administration has issued Announcement No. 59 of 2024 to improve the classification management of medical devices. The announcement details the procedures for classifying medical devices based on regulations and guidelines, focusing on factors like intended use and risks. It covers classification for new devices, uncertain categories, and emergency situations during public health crises. The implementation begins on September 1, 2024, replacing the previous classification notification.

The National Medical Products Administration (NMPA) of China has released new guidelines under the "In Vitro Diagnostic Reagent Classification Catalogue" to update the regulatory framework for the manufacturing and distribution of medical devices. These guidelines necessitate that manufacturers and distributors of in vitro diagnostic reagents adhere to specific licensing and registration processes based on the management categories detailed in their product registration certificates. The NMPA has mandated continued use of the classification "Management Category - 6840 In Vitro Diagnostic Reagents" across various scopes of manufacturing and distribution. Additionally, provincial drug regulatory authorities are instructed to facilitate the training and implementation of these new regulations to ensure compliance and enhance the management of medical devices, particularly focusing on in vitro diagnostic reagents. This initiative is part of the NMPA’s broader efforts to streamline and improve regulatory processes within the medical device sector in China.

China's NMPA introduced significant updates to the management and classification of in vitro diagnostic reagents. These updates include maintaining the validity of existing registrations approved before this date and requiring new registration applications to comply with a revised classification catalogue. The changes also address category adjustments, where products must re-register under the new or old categories depending on risk level adjustments. Additionally, the NMPA will continue processing renewal and change applications received before the effective date under the old catalogue. Class I in vitro diagnostic reagents have a specific transition period until June 30, 2024, after which they must comply with the new catalogue. These revisions aim to enhance the regulatory framework, ensuring the safety and efficacy of in vitro diagnostic reagents in line with current standards.

The National Medical Products Administration (NMPA) of China has released Notification No. 17 of 2024, introducing the "Catalogue of In Vitro Diagnostic Reagent Classification." This initiative is designed to streamline the classification process for in vitro diagnostic reagents as per the "Regulations on the Supervision and Management of Medical Devices" and other related guidelines. The Catalogue delineates the scope and structure of these reagents, excluding those used for legally mandated blood screening and those labeled with radioactive isotopes, and organizes them into a detailed system of 25 first-level and 1,852 second-level categories based on detection targets. It provides a pathway for the management of new products, allowing for direct Class III registration or category determination under the Classification Rules. The notification also specifies the management of various products including culture and cell culture media, and general reagents. Moreover, it announces the repeal of previous related notices, effective January 1, 2025, and highlights the dynamic adjustment of the Catalogue based on ongoing risk analysis and device evaluation. This systematic update aims to ensure regulatory compliance and facilitate the registration and filing processes for in vitro diagnostic reagents.

In April 2024, China's National Medical Products Administration (NMPA) approved 292 medical device products, including various innovative devices such as single-use surgical instruments, advanced diagnostic kits, and therapeutic devices from notable companies like Volcano AtheroMed Inc., Integra LifeSciences, and Abbott Medical. These approvals span across domestic and imported devices, highlighting the NMPA's focus on expanding access to advanced medical technologies.

The National Medical Products Administration of China has unveiled six significant cases of regulatory violations within the medical device sector, emphasizing its dedication to enforcing stringent safety and legality standards. These instances involve various infractions, including the production and distribution of unregistered and expired medical devices, discrepancies in manufacturer information, and submission of falsified documents. Notable cases include Shanghai Youya Pharmaceutical Technology Co., Ltd., which faced hefty fines and confiscation of illegal gains for unauthorized production, and Chongqing Hexi Medical Beauty Clinic, which incurred a major penalty for using non-compliant Class III medical devices. These actions reflect China's proactive approach to ensuring compliance in the medical device industry, aiming to safeguard public health through rigorous regulatory oversight.

Commercial insurance is playing a pivotal role in advancing healthcare access in China, particularly in regions like Hainan and the Greater Bay Area. By covering high costs associated with innovative medical products, insurance is making these treatments more accessible and affordable for patients. This not only aids in quick market entry and expansion for international medical products but also aligns with China's healthcare policies promoting innovation. In areas like the Boao Lecheng International Medical Tourism Pilot Zone in Hainan and the Greater Bay Area, commercial insurance is fostering the creation of international medical hubs, enhancing patient care, and facilitating the integration of cutting-edge medical technologies. This strategic use of insurance supports the broader vision of a modernized, patient-centered healthcare system in China.

The Guangdong Provincial Drug Administration has launched the "Guangdong-Hong Kong-Macao Greater Bay Area (GBA) Medical Pass," a pioneering policy initiative aimed at enhancing real-world medical research within the region. This policy facilitates the use of cutting-edge, clinically urgent medical products in designated institutions, thereby accelerating the approval processes and integrating real-world evidence into regulatory assessments. The initiative was highlighted through the introduction of the PROEM study at a conference in Guangzhou, focusing on the real-world efficacy and safety of Lemborexant in treating insomnia. The robust biopharmaceutical infrastructure in Guangdong supports a range from basic research to clinical applications, underpinning the region's leadership in drug and medical device innovation. As of March 2024, significant progress has been made with 19 institutions approved to participate and 59 types of medical products sanctioned for use, benefiting over 5,000 patients. Looking forward, Guangdong aims to further consolidate its role as a global biopharmaceutical hub by leveraging its industrial strengths and integrating resources across the GBA. This initiative not only underscores the region's commitment to scientific advancement and patient care but also sets a precedent for regulatory innovation in medical research across China.

The interpretation of "Guidelines for the Review of Usability Engineering in Medical Device Registration," published on March 27, 2024, are designed to enhance the usability requirements for Class II and Class III medical devices in China. These guidelines emphasize the critical role of human-machine interaction in medical device design, focusing on ensuring safety, effectiveness, and ease of use through comprehensive usability engineering. They specify processes for usability engineering lifecycle quality control, detail the verification and confirmation of user interfaces, and address the unique challenges associated with imported devices. Additionally, the guidelines discuss how usability engineering relates to clinical trials, the evaluation of existing user interfaces, and the specific considerations for devices used in combination. Application instructions for medical device registration under these guidelines include the submission of usability engineering research reports or use error evaluation reports, depending on the device's risk level. This initiative aims to align China's regulatory standards with international practices, thereby enhancing its global regulatory influence.

On April 2, 2024, China's National Medical Products Administration (NMPA) introduced new guidelines to improve oversight of contract manufacturing in the medical device sector. These measures aim to ensure quality and safety by mandating registrants to maintain robust quality management systems, select capable contract manufacturers, and closely monitor the entire lifecycle of medical devices. Key aspects include the requirement for quality agreements, annual reviews, and stringent oversight by regulatory bodies. The initiative emphasizes collaboration between registrants and manufacturers, enhanced regulatory supervision, and the use of technology for efficient oversight. Set to be implemented on June 1, 2024, these guidelines mark a significant step towards ensuring the integrity and safety of medical devices produced through contract manufacturing.

China's NMPA has escalated its efforts against illegal online sales of medical devices, announcing the fifth batch of enforcement actions on March 27, 2024. This initiative focuses on enhancing online sales supervision and utilizing a national monitoring platform to identify and address illegal activities. Recent investigations have led to penalties for unauthorized sales and sales of unregistered medical devices on various platforms, emphasizing the need for compliance with medical device regulations. The NMPA's strict measures aim to ensure the safety and legality of medical device usage, reinforcing public health protections by penalizing non-compliant practices in the industry.

The National Medical Products Administration (NMPA) issued a clarification on March 27, 2024, regarding the classification of Radiofrequency (RF) Therapy Devices, categorizing certain RF devices for skin treatment as Class III medical devices. This directive, part of the adjustments under Announcement No. 30 (2022), aims to ensure rigorous regulatory oversight for RF devices used in therapeutic skin treatments, emphasizing safety and efficacy. The move by the NMPA sets a clear regulatory path for the development and use of RF therapy devices, aligning with patient safety and product innovation standards.

The National Medical Products Administration (NMPA) has announced a plan to revise 98 medical device industry standards in 2024, aiming to enhance safety, efficacy, and quality in response to evolving healthcare needs in China.

China's National Medical Products Administration (NMPA) has launched the 2024 Medical Device Spot Check Plan, targeting a wide array of devices for quality and safety inspections, mandating provincial drug regulatory authorities and relevant authorities to conduct thorough inspections, address non-compliance with immediate risk control measures and legal actions, and ensure the medical device sector meets the highest safety and efficacy standards, underscoring the country's commitment to public health and regulatory compliance.

On March 19, 2024, the National Medical Products Administration's (NMPA) Center for Medical Device Evaluation in China released the "Guidelines for Usability Engineering in Medical Device Registration," aiming to standardize usability engineering practices for medical devices to ensure their safety and effectiveness through improved user interface design.

China's NMPA CMDE has introduced five new registration review guidelines for specific medical devices, including Monkeypox Virus Nucleic Acid Test Kits, Corneal Topography Devices, Laparoscopic Surgical Systems, and Medical Device Optical Radiation Safety, bringing the total number of effective guidelines to 613 by the end of 2023, covering 92.2% of China's medical device classification catalog.

The National Medical Products Administration (NMPA) is seeking feedback on draft regulations for the supervision and audit of clinical trial institutions for medical devices. These regulations aim to enhance management practices and standardize audit processes. The guidelines, developed in alignment with existing regulations and good clinical practices, outline 16 audit sections and 96 items, covering institution and clinical trial profession aspects. Defects are classified as severe, major, or general, with conclusions drawn based on the severity of non-compliance.

The approval of 193 medical devices by NMPA in February 2024, including advanced Class III and Class II equipment, marks a significant advancement in healthcare technology, catering to diverse medical needs and enhancing patient care.

In March 2024, the National Medical Products Administration approved Hangzhou Dinova's registration application for the innovative "Disposable Heart Pulse Field Ablation Catheter." This catheter, utilized with the company's ablation instrument, delivers targeted pulse field energy to induce precise, irreversible damage to myocardial cells, effectively treating various forms of atrial fibrillation. The product offers expanded treatment options for drug-resistant and recurrent cases, marking a significant advancement in cardiac care.

Abbott Medical's Aveir Leadless Pacemaker VR, designed for patients with severe bradycardia and offering MRI safety and rate-adaptive pacing, has received regulatory approval following extensive clinical and safety evaluations.

The Hengqin Guangdong-Macao In-depth Cooperation Zone introduces VAT and consumption tax refund policies effective from March 1, 2024, to boost economic integration and development, marking a strategic effort to enhance business and trade attractiveness by treating certain imported goods as exports and facilitating tax refunds for qualifying businesses, thus fostering greater economic synergy between Guangdong province and Macao.

In 2023, China significantly advanced its medical device industry by approving and publishing a wide range of national and industry standards, establishing key standardization technical organizations, and reinforcing its commitment to safety, innovation, and global competitiveness.

The "Key Points for the Performance Evaluation Review of Pathological Image AI Analysis Software" provides essential guidelines for the evaluation of AI software in pathology, covering data collection, algorithm performance, and safety standards to ensure the reliability and effectiveness of AI diagnostics tools.

On February 19, 2024, the National Medical Products Administration (NMPA) of China announced the release and implementation of 20 revised and new standards for medical devices, aimed at enhancing product quality, safety, and regulatory compliance across a broad spectrum of medical technologies.

Xiong'an New Area introduces comprehensive measures to support the life sciences and biotechnology sectors, including financial incentives for the industrialization of medical devices, support for international registration and certification of drugs and devices, subsidies for public service platform establishment, encouragement of special medical food industry development, and promotion of pharmaceutical clinical application and research, aiming to foster innovation and position the area as a leading hub in these fields.

In 2023, China significantly advanced its medical device regulatory framework, innovation approval rates, and international standardization efforts, while also enhancing clinical trial, registration, and standard quality management.

A landmark clinical trial for an innovative medical device has shown significant weight loss in subjects, underscoring a commitment to advancing non-surgical obesity treatments and medical technology innovation.

TX Medical News emphasizes the critical need for careful, evidence-based selection of single-arm clinical trial designs in medical device innovation, ensuring safety and efficacy while addressing the unique challenges of groundbreaking technologies.

The NMPA CMDE are advancing medical device innovation with reforms focusing on single-arm study designs to enhance clinical evaluations, ensuring devices meet the highest standards of safety and efficacy for end-users.

The NMPA's approval of Hangzhou Tangji Medical Technology's innovative Gastric Bypass Stent System introduces a non-surgical obesity management solution, promising a safer alternative for effective weight loss.

The "Guidance on Real-World Study Design and Statistical Analysis for Medical Device Registration Review" issued by the NMPA and CMDE on January 10, 2024, revolutionizes the use of real-world data in China's medical device clinical evaluations, enhancing device safety and efficacy assessments in real-life applications.